Hartford Financial Management Inc. Fennec Pharmaceuticals Inc. Transaction History

Hartford Financial Management Inc.

$332 Million
Q2 2025

A detailed history of Hartford Financial Management Inc. transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Hartford Financial Management Inc. holds 50,646 shares of FENC stock, worth $467,969. This represents 0.13% of its overall portfolio holdings.

Number of Shares

50,646

Previous 49,848 1.6%

Holding current value

$467,969

Previous $303,000 38.61%

% of portfolio

0.13%

Previous 0.07%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 31, 2025	BUY	$5.01 - $8.4 $3,997 - $6,703	798 Added 1.6%	50,646 $420,000
Q4 2024 Jan 23, 2025	BUY	$3.99 - $6.37 $3,990 - $6,370	1,000 Added 2.05%	49,848 $315,000
Q2 2024 Aug 09, 2024	BUY	$6.02 - $10.99 $6,321 - $11,539	1,050 Added 2.2%	48,848 $298,000
Q1 2024 Apr 24, 2024	BUY	$8.82 - $11.12 $3,969 - $5,004	450 Added 0.95%	47,798 $531,000
Q4 2023 Jan 29, 2024	BUY	$6.48 - $11.61 $12,960 - $23,220	2,000 Added 4.41%	47,348 $531,000
Q2 2023 Jul 26, 2023	BUY	$7.27 - $9.82 $29,080 - $39,280	4,000 Added 9.67%	45,348 $400,000
Q1 2023 Apr 25, 2023	BUY	$7.38 - $10.35 $11,070 - $15,525	1,500 Added 3.76%	41,348 $344,000
Q3 2022 Oct 25, 2022	BUY	$5.71 - $8.54 $28,550 - $42,699	5,000 Added 14.35%	39,848 $323,000
Q4 2021 Jan 27, 2022	BUY	$3.89 - $10.01 $23,340 - $60,060	6,000 Added 20.8%	34,848 $153,000
Q2 2021 Jul 27, 2021	SELL	$5.96 - $7.85 $29,800 - $39,250	-5,000 Reduced 14.77%	28,848 $210,000
Q1 2021 Apr 14, 2021	SELL	$6.21 - $8.68 $31,050 - $43,400	-5,000 Reduced 12.87%	33,848 $210,000
Q3 2020 Oct 16, 2020	SELL	$5.19 - $10.17 $55,533 - $108,819	-10,700 Reduced 21.6%	38,848 $235,000
Q2 2020 Jul 23, 2020	BUY	$5.43 - $9.39 $40,182 - $69,486	7,400 Added 17.56%	49,548 $414,000
Q1 2020 May 01, 2020	BUY	$4.89 - $8.1 $34,953 - $57,898	7,148 Added 20.42%	42,148 $250,000
Q4 2019 Jan 28, 2020	BUY	$4.25 - $6.49 $21,250 - $32,450	5,000 Added 16.67%	35,000 $227,000
Q3 2019 Oct 28, 2019	BUY	$3.85 - $4.95 $37,345 - $48,015	9,700 Added 47.78%	30,000 $144,000
Q2 2019 Aug 01, 2019	BUY	$3.3 - $5.09 $26,400 - $40,720	8,000 Added 65.04%	20,300 $81,000
Q1 2019 May 08, 2019	BUY	$4.64 - $7.58 $10,672 - $17,434	2,300 Added 23.0%	12,300 $60,000
Q3 2018 Nov 01, 2018	SELL	$7.84 - $10.83 $7,840 - $10,830	-1,000 Reduced 9.09%	10,000 $82,000
Q2 2018 Aug 10, 2018	BUY	$10.05 - $14.33 $20,100 - $28,660	2,000 Added 22.22%	11,000 $115,000
Q1 2018 Apr 10, 2018	BUY	$8.26 - $12.1 $56,581 - $82,885	6,850 Added 318.6%	9,000 $108,000
Q4 2017 Jan 16, 2018	BUY	$8.9 - $12.35 $8,900 - $12,350	1,000 Added 86.96%	2,150 $21,000
Q3 2017 Oct 16, 2017	BUY	$11.09 - $12.0 $12,753 - $13,800	1,150	1,150 $12,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14M

Call Options Held

10K

Put Options Held

83.8K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $241M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hartford Financial Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hartford Financial Management Inc. with notifications on news.

Account

Hartford Financial Management Inc. Fennec Pharmaceuticals Inc. Transaction History